RANZCR examiner reports · fix it Not specific enough Naming the right idea without the dose, interval, threshold or number that earns the mark.
What it looks like: "Start an antibiotic" or "monitor closely" is the idea, not the answer. Marks go to the exact drug, dose, route, interval or threshold, and the options often differ only in those details.
How to fix it: When options differ only in a number, recall the number before you read them. Learn the doses, intervals and cut-offs from the local guidelines, not the general principle.
The drill: 15 questions Questions from the Radiology bank picked because they test this habit. You answer one at a time and see the explanation straight away.
The first 3 are free, below and in the drill with a free account. Any Radiology plan opens all 15.
Try 3 now. No account needed. Question 1 of 3 Musculoskeletal
A 66-year-old man has an IgG paraprotein, 22% clonal plasma cells on bone marrow biopsy, normal calcium, renal function and haemoglobin, and no lytic lesions on whole-body low-dose CT. Whole-body MRI is performed. Which finding would by itself meet the International Myeloma Working Group criteria for active multiple myeloma? A A diffuse low T1 marrow pattern throughout the spine with no focal lesion B A single 14 mm focal lesion in the L2 vertebral body on T1 and STIR C Multiple Schmorl nodes with surrounding marrow oedema in the lumbar spine D Several small focal lesions under 5 mm in the pelvis and proximal femora E Two focal marrow lesions of 8 mm and 11 mm in separate vertebral bodies
Pick an answer to see the explanation. Next question →
Question 1 of 3 · Musculoskeletal
A 66-year-old man has an IgG paraprotein, 22% clonal plasma cells on bone marrow biopsy, normal calcium, renal function and haemoglobin, and no lytic lesions on whole-body low-dose CT. Whole-body MRI is performed. Which finding would by itself meet the International Myeloma Working Group criteria for active multiple myeloma?
A diffuse low T1 marrow pattern throughout the spine with no focal lesion A single 14 mm focal lesion in the L2 vertebral body on T1 and STIR Multiple Schmorl nodes with surrounding marrow oedema in the lumbar spine Several small focal lesions under 5 mm in the pelvis and proximal femora Two focal marrow lesions of 8 mm and 11 mm in separate vertebral bodies Show the answer E. Two focal marrow lesions of 8 mm and 11 mm in separate vertebral bodies
Under the 2014 IMWG criteria, more than one focal lesion of 5 mm or more on MRI is a myeloma-defining event (the "SLiM" criteria, alongside 60% or more clonal plasma cells and a free light chain ratio of 100 or more), so this patient has active myeloma and needs treatment rather than observation. A single lesion warrants follow-up imaging.
Why not A: A diffuse pattern is associated with worse prognosis but is not a defining event alone. Why not B: A single lesion does not meet the threshold; repeat MRI in 3-6 months is advised. Why not C: Schmorl nodes are degenerative and unrelated to myeloma. Why not D: Lesions under 5 mm do not count towards the criterion. Question 2 of 3 · Physics, imaging technology & radiation safety
After a 3-hour transjugular intrahepatic portosystemic shunt procedure, the angiography unit reports a cumulative air kerma (CAK) of 5.8 Gy and a kerma-area product (KAP) of 380 Gy·cm². Most imaging was posteroanterior, with little gantry angulation. Which statement about this patient's skin dose is most accurate?
The peak skin dose equals the CAK, because the CAK is measured at the entrance skin surface of the patient and already includes backscatter The KAP is below 500 Gy·cm², so no follow-up is needed whatever the CAK is, because KAP is the best predictor of deterministic skin injury The CAK has passed the 5 Gy substantial radiation dose level, so the patient needs documented counselling and skin review even though peak skin dose may differ from CAK The peak skin dose must be lower than the CAK, because the reference point always lies further from the source than the skin of the patient Fluoroscopy time of 3 hours is the best single measure of the risk of skin injury, so the dose indices can be ignored in the report Show the answer C. The CAK has passed the 5 Gy substantial radiation dose level, so the patient needs documented counselling and skin review even though peak skin dose may differ from CAK
CAK is an index of skin dose at a fixed reference point, not the skin dose itself. Peak skin dose can be lower (beam moved around, table attenuation) or higher (skin closer to source, little angulation, large patient). NCRP Report 168 substantial radiation dose levels are peak skin dose 3 Gy, CAK 5 Gy, KAP 500 Gy·cm² and fluoroscopy time 60 minutes; exceeding any one should trigger documentation, patient notification and skin follow-up.
Why not A: CAK is measured at the interventional reference point 15 cm from isocentre towards the source and excludes backscatter and table attenuation. Why not B: KAP correlates with stochastic risk; CAK and peak skin dose are better indicators of skin dose. Any one threshold exceeded triggers follow-up. Why not D: With little angulation and a large patient the skin can be closer to the source than the reference point, so peak skin dose can exceed CAK. Why not E: Fluoroscopy time ignores dose rate, acquisition runs and field size and is the weakest indicator. Question 3 of 3 · Abdominal & GI/GU
A 70-year-old woman has a cystic lesion in the head of the pancreas that communicates with the pancreatic duct, consistent with a branch-duct intraductal papillary mucinous neoplasm (IPMN). Which finding on MRI is a high-risk stigma under the 2017 international (Fukuoka) consensus guidelines?
Cyst diameter of 34 mm with smooth thin walls and no nodules Enhancing mural nodule of 3 mm within the cyst on post-contrast images Main pancreatic duct dilated to 11 mm along the body and tail Cyst growth of 6 mm over two years with stable duct calibre Abrupt main duct calibre change with distal pancreatic atrophy Show the answer C. Main pancreatic duct dilated to 11 mm along the body and tail
High-risk stigmata are obstructive jaundice with a head lesion, an enhancing mural nodule of 5 mm or more, and main duct dilatation to 10 mm or more; they warrant surgical referral if the patient is fit. Cyst size of 3 cm or more, smaller nodules, duct 5-9 mm, abrupt calibre change, growth of 5 mm or more over two years and raised CA19-9 are worrisome features that prompt endoscopic ultrasound.
Why not A: A cyst of 3 cm or more is a worrisome feature, not a high-risk stigma. Why not B: A nodule under 5 mm is worrisome; 5 mm or more is high risk. Why not D: Growth of 5 mm or more in two years is a worrisome feature. Why not E: Abrupt calibre change with distal atrophy is a worrisome feature. Create a free account to save your results and keep going →
Where the RANZCR examiners flagged it Vague or incomplete findings, writing the diagnosis as a finding, and wrong terminology (calcification for ossification; not using IOTA or O-RADS descriptors for an adnexal mass). Phase 1 physics: confusing cumulative air kerma with peak skin dose, dose-length product with effective dose, and what percentile a diagnostic reference level sits at; vague accounts of iterative reconstruction. All RANZCR examiner reports →
Fellowship Ready is not affiliated with or endorsed by the RANZCR. Not affiliated with the Royal Australian and New Zealand College of Radiologists (RANZCR).